Staphylococcal scalded skin syndrome

Summary

Staphylococcal scalded skin syndrome (MONDO:0018181) is a disease. A subtype of commensal bacterial infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	<1 / 1 000 000	0.01	Germany	Not yet validated

Identifiers

Disease identifiers

Field	Value
Canonical name	staphylococcal scalded skin syndrome
Mondo ID	MONDO:0018181
EFO	EFO:0007473
MeSH	D013206
Orphanet	36236
DOID	DOID:9063
ICD-10-CM	L00
ICD-11	1554593739
NCIT	C85077
SNOMED CT	200946001, 277475006
UMLS	C0038165
MedGen	52484
GARD	0013158
MedDRA	10041929
NORD	1781
Is cancer (heuristic)	no

Also known as: generalised exfoliative disease · generalized exfoliative disease · Ritter disease · Ritter’s disease · SSSS · staphylococcal scalded skin syndrome

Disease family

This is a subtype of commensal bacterial infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › commensal bacterial infectious disease › staphylococcal scalded skin syndrome

Related subtypes (5): toxic shock syndrome, actinomycosis, chlamydia trachomatis infectious disease, gas gangrene, Lemierre syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.